JSM 2015 Preliminary Program

Online Program Home
My Program

Legend: Washington State Convention Center = CC, Sheraton Seattle = S, Grand Hyatt = GH and The Conference Center = TCC
* = applied session       ! = JSM meeting theme

Activity Details
324 Tue, 8/11/2015, 8:30 AM - 10:20 AM CC-611
Emerging Topics in Benefit-Risk Assessment in Clinical Development Decision-Making — Contributed Papers
Biopharmaceutical Section
Chair(s): John Han,
8:35 AM The Use of Adaptive Designs in Antiviral Drug Development — Fraser Smith, FDA/CDER/OTS/OB/DBIV ; Karen Qi, FDA/CDER/OTS/OB/DBIV
8:50 AM Missing Data Handling for Composite Endpoints — Sabrina Wan, Merck ; G. Frank Liu, Merck ; Weili He, Merck
9:05 AM Graphical Presentation of Benefit-Risk Profile — Weili He, Merck ; Shihua Wen, AbbVie ; Scott R. Evans, Harvard University
9:20 AM What Is the Role of Statisticians in Benefit-Risk Adoption Within Our Companies? — Susan P. Duke, GlaxoSmithKline ; Greg Anglin, Eli Lilly Corporation
9:35 AM Multiplicity and Subgroups in Benefit-Risk Assessment — Jonathan Norton
9:50 AM Structured Benefit-Risk Assessment Across the Lifecycle of Products: Methods, Examples, and Challenges — Chunlei Ke ; George Quartey, Roche ; Christy Chuang-Stein, Pfizer Inc. ; John Scott, FDA ; Qi Jiang, Amgen ; Weili He, Merck ; Ramin Aramin, AstraZeneca ; Guochen Song, Quintiles ; Kao-tai Tsai, Celgene ; Yujun Wu, Sanofi
10:05 AM Some Thoughts on Benefit-Risk Assessment for Drug Development — Qi Jiang, Amgen




For program information, contact the JSM Registration Department or phone (888) 231-3473.

For Professional Development information, contact the Education Department.

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

2015 JSM Online Program Home